Charles River Laboratories faces a prolonged biotech funding winter, with revenue flat to declining over eight consecutive quarters (2026Q2 down 2.7% YoY to $1.0B). While gross margin improved to 36.2% in 2026Q2, operating leverage remains stalled, and net los...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been stagnant for eight quarters, with 2026Q2 down 2.7% YoY to $1.0B, and while gross margin expanded to 36.2%, operating margin at 11.9% remains below the 14.8% peak in 2024Q2, and net margin is negative at -0.1%.
The company is projected to achieve a 500-basis-point margin expansion in the second half of 2026, which could significantly improve profitability.
Revenue has shown consistent growth, ranging between US$984.2 million and US$1,032.1 million in the first half of FY 2025.
The company possesses a narrow moat, indicating a competitive edge in its industry that supports sustained profitability.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $3.02+10.2% vs $2.74 | $1.0B+2.8% vs $977M |
Q2 2026 May 7, 2026 | $2.06+5.1% vs $1.96 | $996M+1.9% vs $977M |
Q1 2026 Feb 18, 2026 | $2.39+2.6% vs $2.33 | $994M+0.7% vs $987M |
Q4 2025 Nov 5, 2025 | $2.43+4.7% vs $2.32 | $1.0B+1.8% vs $987M |
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv.
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark CRL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Charles River Laboratories International, Inc. (CRL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $277.33 | $13.36B | -95.30 | -0.85% | -3.59% | -4.3% | — | |
| $267.86 | $44.09B | 34.17 | 5.87% | 8.1% | 21.51% | — | |
| $617.15 | $17.23B | 40.39 | 19.97% | 17.67% | 110.15% | — | |
| $163.90 | $12.55B | 56.52 | -0.37% | 3.99% | 3.54% | — | |
| $25.00 | $1.29B | 25.25 | -2.67% | 6.04% | 4.95% | — | |
| $18.27 | $2.98B | 20.53 | -7.16% | 2.92% | 6.08% | — |
Charles River Laboratories International, Inc. (CRL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Charles River Laboratories International, Inc. (CRL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 11, 2026·SEC
May 7, 2026·SEC
Get notified when CRL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Charles River Laboratories International, Inc. (CRL) stock FAQ — growth, dividends, profitability & financials explained
Charles River Laboratories International, Inc. (CRL) reported $4.00B in revenue for fiscal year 2025. This represents a 1969% increase from $193.3M in 1998.
Charles River Laboratories International, Inc. (CRL) saw revenue decline by 0.9% over the past year.
Charles River Laboratories International, Inc. (CRL) reported a net loss of $238.5M for fiscal year 2025.
Charles River Laboratories International, Inc. (CRL) has a return on equity (ROE) of -4.3%. Negative ROE indicates the company is unprofitable.
Charles River Laboratories International, Inc. (CRL) generated $370.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
